These findings suggest that the tissue-specific actions of PPARγ may help explain how systemic PPARγ activation yields hepatoprotective effects and improves MASLD/MASH outcomes. The gene discussed is PPARG; the disease is metabolic dysfunction-associated steatohepatitis.